Observational studyAnnals of African medicine2025
Radiological Outcomes in Recovered COVID-19 Pneumonia Cases at 1-year Follow-up: The "Post-COVID-19 Lung Study" in Dedicated COVID-19 Care Setting in India.
Observational study in Annals of African medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiological outcomes are initially interpreted as post-COVID-19 lung fibrosis in short-term follow-up of recovered COVID-19 cases in post-COVID-19 care settings and during long-term evaluation, these abnormalities are defined as post-COVID-19 sequalae's. In the present study, post-COVID-19 lung abnormalities were evaluated as "residual lung abnormalities (RLAs)" as radiological outcomes phenotypes.
methodsProspective, observational study initially included 1000 COVID-19 reverse transcription-polymerase chain reaction confirmed cases with lung involvement documented and radiological severity phenotypes categorized on high-resolution computerized tomography (HRCT) thorax as mild, moderate, and severe as per lung segment involvement bilaterally at the entry point. Final radiological outcomes were defined by performing a radiological assessment done at 1 year of discharge from the hospital in cases with specified inclusion criteria. Radiological final outcome phenotypes were defined as radiological lung abnormalities (RLAs) and categorized as resolving, persistent, and progressive types documented in HRCT imaging at 1 year of follow-up. Finally, we have included 209 cases with RLAs. Covariates recordings of age, gender, comorbidity, laboratory parameters, and interventions such as oxygen support and oxygen plus ventilatory support requirement during hospitalization were done. Statistical analysis is done using Chi-square test.
resultsRLAs were documented in 20.73% (209/1000) cases. Final radiological outcomes were documented as resolving at 72.24% (151/209), persistent 19.61% (41/209), and progressive 8.13% (17/209). A significant association was documented between RLAs and duration of illness at the entry point ( P < 0.00001), laboratory parameters at the entry point (D-dimer, C-reactive protein, interleukin-6) ( P < 0.00001), radiological computerized tomography severity phenotypes ( P < 0.00001), and interventions required in the indoor unit ( P < 0.00001). A significant association was observed between RLAs with covariates such as age, gender, diabetes mellitus, ischemic heart disease, hypertension, chronic obstructive pulmonary disease, obesity, and lung functions assessment by spirometry at 1 year follow-up ( P < 0.00001).
conclusionsRadiological lung abnormalities (RLAs) are new radiological classification of post-COVID-19 lung sequelae and are categorized as resolving, persistent, and progressive. Final outcomes phenotypic classification showed an important role in further workup and treatment plannings of these RLAs during follow-up. Importantly, the proportionate number of progressive phenotypes has underlying rheumatological predisposition, and the large number of cases in resolving phenotypes doesn't need any treatment; whereas few cases in the persistent category need protocolized follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.